PCSK9 and osteonecrosis: In contrast, other drug targets (APOC3, NPC1L1, PCSK9, APOB, CETP, LDLR and LPL) exhibited neutral effects on osteonecrosis outcomes based on their genetic resemblances (Figure 2C,D).